They offer essential preclinical data to guide dose optimization in longitudinal studies using TfRMAb-based therapeutics, specifically modified-EPO, and show the robust therapeutic potential of low-dose brain-penetrating EPO in the APPSAA KI AD mouse model. Here, EPO is linked to Alzheimer disease.